Related Experiment Video
Updated: May 20, 2025
10:50
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
7.6K
Current and emerging therapies for autoimmune encephalitis.
Darina Dinov1, Linda Nguyen2, Kyle Blackburn1
1Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Expert Review of Neurotherapeutics
|March 24, 2025
Summary
Autoimmune encephalitis (AIE) is an inflammatory brain disorder treated with immunotherapy. This review examines current treatments for AIE subtypes like anti-NMDAR and LGI1 encephalitis, highlighting evidence gaps and future therapeutic directions.
Area of Science:
- Neurology
- Immunology
- Neuroinflammation
Background:
- Autoimmune encephalitis (AIE) is an inflammatory neurological disorder characterized by autoantibodies against neural or glial antigens.
- Current immunotherapy strategies for AIE exist, but optimal treatment protocols for specific subtypes remain unclear.
Purpose of the Study:
- To review the pathophysiology of AIE based on autoantibody targets (cell surface vs. intracellular antigens).
- To discuss current immunotherapy treatments for AIE, including side effect management and monitoring.
- To examine evidence for treatment approaches in anti-NMDAR and LGI1 encephalitis and provide an outlook on future therapies.
Main Methods:
- Literature search of PubMed and Google Scholar (2005-2024) using keywords: 'autoimmune encephalitis,' 'anti-NMDA receptor encephalitis,' 'LG1 encephalitis.'
Main Results:
- AIE pathophysiology varies depending on autoantibody targets.
- Evidence for specific AIE treatments is largely from observational studies, necessitating further clinical trials.
- Ongoing clinical trials and emerging targeted therapies offer promise for improved patient outcomes.
Conclusions:
- Immunotherapy benefits patients with AIE, but robust evidence for optimal strategies is limited.
- Future clinical trials are crucial for establishing effective treatment guidelines and developing targeted therapies for AIE subtypes.
Related Concept Videos
01:30Electroconvulsive Therapy
20
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
20
01:27Tumor Immunotherapy
450
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
01:20Myasthenia Gravis: Overview and Treatment
1.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.0K